- Rentokil sees a total first quarter revenue of GBP1.27 billion.
- The largest chunk of this revenue comes from North America, contributing GBP761 million.
- Europe’s revenue stands at GBP274 million.
- The UK and Sub-Saharan Africa contribute GBP103 million to the total revenue.
- Asia and the MENAT region bring in GBP86 million in revenue.
- France workwear alone adds GBP57 million to the revenue.
- Rentokil is hopeful for continued progress throughout the year, driven by a focus on growth in North America.
- Integration plans with Terminix are in the advanced stages, with full branch integrations scheduled to commence mid-year.
- There are 11 buy ratings, 5 hold ratings, and 2 sell ratings on Rentokil’s performance.
A look at Rentokil Initial Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Rentokil Initial, a company that offers essential support services to various organizations, has received mixed ratings on its key performance factors according to Smartkarma Smart Scores. With strong scores in Growth and Momentum, the company seems positioned for long-term success in terms of expanding business opportunities and maintaining positive market momentum.
On the other hand, Rentokil Initial has average scores in Value, Dividend, and Resilience, indicating some areas for potential improvement or further evaluation. Despite this, the company’s robust services in pest control, hygiene, workwear, and facilities, highlight its diverse offerings in the facilities management sector, which could contribute to its overall resilience in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
